Marisa Lozano
Papers
1
Total Citations
3
H-Index
1
About
Marisa Lozano is a clinical researcher advancing the frontiers of prostate cancer treatment, with a focused expertise in neoadjuvant therapy and surgical oncology. Her most impactful work centers on optimizing preoperative regimens for intermediate-risk prostate cancer patients, aiming to reduce the need for postoperative radiation therapy. In her landmark Phase II study, Lozano investigated a six-month course of apalutamide prior to radical prostatectomy, demonstrating a strategic approach to diminish pathologic features that typically necessitate adjuvant radiation. This work, published in the *Journal of Urology* (2021), has garnered early citations from peers seeking to refine multimodal treatment paradigms. While her citation count is still building—reflecting the nascent stage of this innovative trial—Lozano’s contribution is notable for its potential to shift clinical practice by sparing patients from additional radiation and its associated toxicities. Her research bridges the gap between pharmacologic intervention and surgical outcomes, offering a personalized, less invasive path for men with localized disease. As a rising voice in urologic oncology, Lozano’s work underscores a commitment to reducing treatment burden while maintaining oncologic control.
Research Focus
Key Achievements
Top Papers
- 1